GlassScriptPhysician profile
Kindra J Clark
NPI 1558765727
$10,868.81
in general payments reported to CMS, 2019-2025
34 companies · $3,863 in 2025
The $3,863 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $2,489 · 2024: $4,517 · 2025: $3,863.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,868.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $1,251.66 | 2023-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $917.38 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Abbott Laboratories | $821.71 | 2023-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $813.10 | 2023-2025 | Jardiance, Synjardy, Tradjenta |
| Ascensia Diabetes Care US INC. | $740.72 | 2023-2025 | |
| Lilly USA, LLC | $699.91 | 2023-2025 | Jardiance, Mounjaro, Zepbound |
| Novartis Pharmaceuticals Corporation | $693.35 | 2023-2025 | |
| Corcept Therapeutics | $631.13 | 2023-2025 | Korlym |
| Cequr Corporation | $560.13 | 2023-2025 | Cequr Simplicity |
| Mannkind Corporation | $537.00 | 2023-2025 | Afrezza |
| Medtronic, INC. | $530.83 | 2023-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Xeris Pharmaceuticals, INC. | $383.14 | 2023-2025 | Recorlev, Gvoke Hypopen |
| Amgen INC. | $381.54 | 2023-2025 | Repatha, Evenity, Prolia |
| Radius Health, INC. | $303.21 | 2023-2025 | Tymlos |
| Recordati_rare_diseases_inc. | $240.68 | 2023-2025 | Signifor Lar, Isturisa |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $214.28 | 2023-2025 | Crysvita |
| Sequel Med Tech, LLC | $213.86 | 2025 | Twiist |
| Bayer Healthcare Pharmaceuticals INC. | $190.70 | 2023-2025 | |
| Insulet Corporation | $107.19 | 2025 | Omnipod |
| Alexion Pharmaceuticals, INC. | $89.47 | 2023-2025 | Strensiq |
| Soleno Therapeutics, INC. | $80.81 | 2025 | Vykat Xr |
| Sanofi-Aventis U.S. LLC | $79.52 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $77.09 | 2023-2024 | Farxiga |
| Abbvie INC. | $62.45 | 2024-2025 | |
| Madrigal Pharmaceuticals | $47.89 | 2025 | Rezdiffra |
| Averitas Pharma INC. | $33.97 | 2025 | Qutenza |
| Pfizer INC. | $28.18 | 2024-2025 | |
| Beta Bionics, INC. | $26.15 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Amarin Pharma, INC. | $21.61 | 2023 | |
| Halozyme INC | $21.18 | 2023 | |
| Antares Pharma, INC. | $20.90 | 2023 | Nocdurna, Xyosted, Tlando |
| Glaxosmithkline, LLC. | $20.84 | 2025 | Shingrix, Arexvy |
| Esperion Therapeutics, INC. | $13.71 | 2025 | Nexletol |
| Tolmar, INC. | $13.52 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kindra Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.